This phase II trial is evaluating how well combinations of chemotherapy (UH-3 and ICE/Cyclo/Tropo) work in treating children, adolescents and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilm's Tumour (DAWT) or relapsed favourable histology Wilm's Tumour (FHWT)Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Summary

This is a non-randomised, open-label study investigating the effects of different regimens of chemotherapy in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's tumours (DAWT) or relapsed favourable histology Wilm's Tumours (FHWT). Participants will DAWT and standard-risk relapsed FHWT will receive the UH-3 chemotherapy regimen, which includes vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with high- and very-high risk FHWT will receive the ICE/Cyclo/Tropo chemotherapy regimen, which includes ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan. All treatments will be administered intravenously (via IV).